Truist analyst Richard Newitter raised the firm’s price target on Integer (ITGR) to $150 from $140 and keeps a Buy rating on the shares. Integer beat estimates in Q1 on EPS and organic revenue amid strength in Cardio and Vascular, and guidance for 8%-10% organic growth for fiscal 2025 was reiterated, while EPS guidance was increased, the analyst tells investors in a research note. Truist thinks the outlook leaves room for upside as the year progresses and continues to believe that the company can profitably grow above its end markets.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas” class=”link “>Try Now>>

>;elm:context_link;itc:0;sec:content-canvas” class=”link “>See the top stocks recommended by analysts >>

Read More on ITGR:

Disclaimer & DisclosureReport an Issue